NCT01702207View on ClinicalTrials.gov

Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
ImmunosuppressionCardiovascular DiseasesKidney Transplantation
Interventions
DRUG

Once Daily Tacrolimus

Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.

DRUG

Twice Daily Tacrolimus

Subjects are kept on Prograf® which is the Twice Daily Tacrolimus

Trial Locations (1)

S7M0Z9

St Paul's Hospital, Saskatoon

All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

University of Saskatchewan

OTHER

NCT01702207 - Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk | Biotech Hunter | Biotech Hunter